Effect of early immunomodulator use in moderate to severe pediatric Crohn disease.
BACKGROUND
The immunomodulators (IMs) 6-mercaptopurine and azathioprine decrease corticosteroid dependence and maintain remission in Crohn's disease (CD). We describe IM use in newly diagnosed pediatric CD, comparing outcomes of "early" versus "late" initiation of therapy.


METHODS
Data were obtained from pediatric CD patients enrolled in a prospective, multicenter observational study. Moderate/severe disease patients treated with IM were compared for outcomes of remission, corticosteroid use, infliximab therapy, hospitalizations, and CD-related surgery based on timing of initiation of IM therapy.


RESULTS
In all, 247 children met the criteria (60% male, mean age 11.9 years); 199 were treated with IM within 1 year of diagnosis; 150 between 0-3 months (early), 49 between 3-12 months (late). Both groups showed a decrease in corticosteroid use by 12 months, at which time proportionately fewer early group patients had received corticosteroids in the preceding quarter (22%) than late groups patients (41%)(P = 0.013). The number of hospitalizations per patient was also noted to be significantly lower in the early group over the 2-year follow-up (P = 0.03). No difference was noted in the rates of remission, infliximab use over time, or surgery.


CONCLUSIONS
80% of children with newly diagnosed moderate to severe CD are treated with IM within 1 year. Early IM use is associated with reduced corticosteroid exposure and possibly fewer hospitalizations per patient.
Punati
Jaya
J
Nationwide Children's Hospital, Ohio State University, Columbus, Ohio 43210, USA. Jaya.Punati@NationwideChildrens.org
Markowitz
James
J
Lerer
Trudy
T
Hyams
Jeffrey
J
Kugathasan
Subra
S
Griffiths
Anne
A
Otley
Anthony
A
Rosh
Joel
J
Pfefferkorn
Marian
M
Mack
David
D
Evans
Jonathan
J
Bousvaros
Athos
A
Moyer
M Susan
MS
Wyllie
Robert
R
Oliva-Hemker
Maria
M
Mezoff
Adam
A
Leleiko
Neal
N
Keljo
David
D
Crandall
Wallace
W
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001379:Azathioprine / Q000008:administration & dosage; D002648:Child; D003424:Crohn Disease / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006760:Hospitalization; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D000069285:Infliximab; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D011446:Prospective Studies
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D007155:Immunologic Factors; D000069285:Infliximab; D015122:Mercaptopurine; D001379:Azathioprine